PATH-FOR-YOUNG Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients
- Coordinator
- Unicancer, France
- Runs
- 1 January 2025 to 31 December 2031
- Status
- Running
- EU funding
- €9.5m
- Total cost
- —
- Partners
- 27 organisations in 15 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101156800
What the project is doing
In the project's own words, from its summary on CORDIS.
Worldwide, ~7 million women live with or beyond Breast Cancer (BC), as 10-year survival rates exceeding 80% for early-stage (I-III) BC. Premenopausal BC accounts for 25% in the EU and 55% in low/middle income countries. Most premenopausal women with BC have high risk of recurrence, therefore standard treatment includes adjuvant chemo- (CT) and endocrine therapy (ET). However, treatment has substantial physical, emotional and social burden, which is often more pressing for younger compared to older patients.
Gene-expression assays are used for post-menopausal patients to identify women who can safely forego CT without detriment on clinical outcomes, preserving Quality of Life (QOL). However, a definitive study has yet to be conducted among premenopausal women with high-risk HR+HER2-BC. The primary objective of PATH-FOR-YOUNG is to conduct a pragmatic randomized controlled trial (RCT) with 5000 patients validating the use of a gene-expression assay to drive adjuvant treatment decisions in this target population.
PATH-FOR-YOUNG aims to achieve its objective in 7 years. The project (i) builds on and complements an ongoing twin RCT to ensure timely recruitment, (ii) leverages on a large international consortium of oncologists, pathologists, patient representatives, psychologists, sociologists, ethics and communication experts, biostatisticians, health economists, and technology providers, to assure complementary and multidisciplinary expertise, and (iii) highlights patient-engagement, participatory care, and early involvement of end users.
PATH-FOR-YOUNG will also study implementation of digital self-management to support patients throughout the cancer journey and particularly while on ET to improve QOL and medication adherence. A full HTA will ensure a path towards cross-country implementation. PATH-FOR-YOUNG has the ambition to improve BC care, fully integrating the predictive, personalized, preventive, and participatory principles of health management.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Unicancer | Paris | France | Coordinator |
| Grupo Argentino De Investigacion Clinica En Oncologia Asociacion Civil | Rosario | AR | Participant |
| ANZ Breast Cancer Trials Group Ltd | Newcastle | Australia | Associatedpartner |
| The University of Sydney | Sydney | Australia | Associatedpartner |
| Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules Bordet | Anderlecht | Belgium | Participant |
| Breast International Group, B.i.g.aisbl | Bruxelles | Belgium | Participant |
| Instituto D'Or de Pesquisa e Ensino | Niterói | Brazil | Associatedpartner |
| Latin American Cooperative Oncology Group | Porto Alegre | Brazil | Associatedpartner |
| Elliniki Synergazomeni Ogkologiki Omada | Athens | Greece | Participant |
| Gr Espanol De Estudio Y Tratamientode Intensific. Y Otras Estrateg.experiment. En Tumores Solidos - Grupo Solti | Barcelona | Spain | Participant |
| Innovandum Health SL | Valencia | Spain | Participant |
| Universidad De Castilla - La Mancha | Ciudad Real | Spain | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Klineo | Clichy | France | Participant |
| Resilience | Paris | France | Participant |
| Cancer Trials Ireland Company Limited by Guarantee | Dublin | Ireland | Participant |
| Clinical Research Technology SRL | Salerno | Italy | Participant |
| Europa Donna the European Breast Cancer Coalition | Milano | Italy | Participant |
| Gruppo Oncologico Italiano Di Ricerca Clinica | Parma | Italy | Participant |
| Universita Degli Studi Di Torino | Torino | Italy | Participant |
| Stichting Eupati Foundation | Utrecht | Netherlands | Participant |
| Grupo De Estudios Clinicos Oncologico Peruano Gecoperu | Santiago de Surco | PE | Participant |
| Central and East European Oncology Group | Gdansk | Poland | Participant |
| Europa Donna Slovensko Zdruzenje Za Boj Proti Raku Dojk | Ljubljana | Slovenia | Third party |
| University of Warwick | Coventry | United Kingdom | Participant |
| Dana-Farber Cancer Institute Inc | Boston Ma | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI